@oatila Inclusive essa publicação na mesma revista científica comenta sobre a possibilidade de termos uma vacina eficiente em tempo recorde e os avanços das principais que estão em pesquisa. Mas esse tipo de estudo ele não comenta. Não acho que seja por ac
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
A brief Nature Reviews: Drug Discovery piece summarizing the global development activity towards vaccines to protect against COVID. It’s heartening to see the speed with which many smaller companies have stepped up. Production will eventually require the l
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
RT @JeremyFarrar: Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target…
Summary early April vaccine R&D SARS-CoV-2. Progress since as these & others into clinical trials. Need to broaden target of vaccines most focus on spike protein of virus. Need to broaden to prevent immune escape & ensure antibody & cellula
RT @CaloriesProper: COVID umbrella trials multiply https://t.co/mAeIn56gWn the trials: RECOVERY, SOLIDARITY, ACTT, PRINCIPLE, REMAP-CAP,…
COVID umbrella trials multiply https://t.co/mAeIn56gWn the trials: RECOVERY, SOLIDARITY, ACTT, PRINCIPLE, REMAP-CAP, ACCORD, and ACTIV... and 115 vaccines in development https://t.co/Tu8cEcqEhc
@thatsonofjacob @News24 WHO is not developing a vaccine. Over 100 independent projects https://t.co/dQ2HsH6uwe
RT @pcorrea78: Hay 78 candidatas para la vacuna COVID-19, cinco de las cuales ya están en etapa de ensayos clínicos. https://t.co/BsOk9XBNS…
Број непрофитних и академских центара који развијају вакцину за ковид19 знатно је мањи (30%) од бр приватних индустријских центара (70%): Т.Thanh Le et al. Nature Rev. Drug. Disc. https://t.co/qDSjEueqk1 (2020). Логика профита прети да угрози клин. прист
RT @pcorrea78: Hay 78 candidatas para la vacuna COVID-19, cinco de las cuales ya están en etapa de ensayos clínicos. https://t.co/BsOk9XBNS…
@MerielMyers Current forerunner is moderna's RNA vaccine. Yup. https://t.co/P8Mipvb6CS
@stavkitrinos @VadersDeLorean @Aldamir @Avik @razibkhan @biorxivpreprint "There’s no chance it’s not a RNA vaccine ..." Umm ... see the legend at upper right, below. https://t.co/7cK5kA3hEG https://t.co/8OzMUsJPXf
@Glenntabe11 I'd love for you to share where you read this from. I can share a few links with you as well; https://t.co/VrY2ybBfli https://t.co/JRyX6NIj5Y Second link has a pdf attached.
The COVID-19 vaccine development landscape https://t.co/6NklhQeeJc
Reference : https://t.co/k7cgbRl0i0
Tambahan: beberapa kandidat vaksin covid-19 aja masih dites dan baru bisa dipake secara darurat awal 2021 nanti https://t.co/GM6AJKQYGK.
The COVID-19 vaccine development landscape https://t.co/EoWtlfgQaa
Interesante gráfica que muestra los principales grupos trabajando en una vacuna para el COVID-19, con el sector privado a la cabeza https://t.co/cMfjubIFLi https://t.co/NsllafgiSU
@robbysoave @DanFosterType I think it's a function of the massive work being done on an unprecedented scale & pace by multiple respectable figures. It could still easily not come to pass but it's not as implausible as it would have been 6 months ago ht
The COVID-19 vaccine development landscape https://t.co/Onb8CTTasx
The #COVID19 vaccine development landscape https://t.co/rNceVEnIBk by @nature https://t.co/PXLhm2x1Js
@fuxsuxlux อันนี้ฝากไว้หากใครอยากอ่านงานวิจัยเรื่องการพัฒนาวัคซีนแบบจริงจัง ในหลายๆประเทศค่ะ https://t.co/GwImkeDeFu
@MVirtanen @VilleNiinisto https://t.co/l2RRXhtk7s Aika kattava katsaus. Mitä tuosta osaisi nostaa esille? Eiköhän lie aika vahva arvio, että immuniteetin antava rokote syntyy...joskus. "...early 2021...emergincy use..."
RT @chris_m_h: My best COVID-19 reads: Risks, how to avoid them, @erinbromage https://t.co/j6xyfZQVkS Future vaccines, @nature https://t…
y distribuidas de manera equitativa en todas las áreas afectadas, particularmente en regiones de bajos recursos. 💪👩👩👧👦 Adaptado de “The COVID-19 vaccine development landscape”, Tung Thanh Le, Nature Reviews Drug Discovery 19, 305-306 (2020). https://t.
My best COVID-19 reads: Risks, how to avoid them, @erinbromage https://t.co/j6xyfZQVkS Future vaccines, @nature https://t.co/PzslJv2yoG What we can do (value of homemade masks) @tomaspueyo https://t.co/50BmJC6eCg Vaccines/treatment/cures, @BillGates
@Olivergh_geo La única esperanza, y no está garantizada https://t.co/mYZGHzx5tx
CLINICAL-PHASE VACCINE CANDIDATES FOR COVID-19 https://t.co/nMZY6imzpu
Vaccine development typically averages a timeline of over a decade, so it’s exciting and inspiring to see signs that emergency COVID-19 vaccines could be ready by 2021. But, they must also be able to overcome the challenges of large-scale manufacture. htt
RT @ScienceMarchDEN: The SARS-CoV-2 genome does not include any markers that would accompany human manipulation: https://t.co/aoMy8Jg1Q1 A…
The SARS-CoV-2 genome does not include any markers that would accompany human manipulation: https://t.co/aoMy8Jg1Q1 At least 78 vaccines are in development, but none have released clinical trial data to date: https://t.co/NKpcX91Ujy To reclaim a phrase:
RT @mtesanz: The Covid19 vaccine developement landscape https://t.co/v1HzVSpPZg
The Covid19 vaccine developement landscape https://t.co/v1HzVSpPZg
The COVID-19 vaccine development landscape https://t.co/XqUvCPSywx
The COVID-19 vaccine development landscape https://t.co/ALAHJ3Rwea
The COVID-19 vaccine development landscape https://t.co/nPG1q6pQO5
The COVID-19 vaccine development landscape https://t.co/QeU250l2HO
#COVIDVACCINE - 115 candidates in testing & clinical trials... https://t.co/fNyj8Wi9j4 https://t.co/ZSRnMpGM2A
RT @ADNDaniel: Hay más de 90 #vacunas candidatas en desarrollo para frenar la #pandemia de #covid19. En su opinión, ¿Por qué ninguna #sta…
@etrnlygr8tful @ele_jen @Conrad_DeJong Well that didn't go so well for Dengvaxia or the HPV vaccine and likely not for a fast-tracked covid vaccine. We don't know about what kind it will be but DNA and RNA vaccines are strong contenders. https://t.co/5vgbc
RT @ADNDaniel: Hay más de 90 #vacunas candidatas en desarrollo para frenar la #pandemia de #covid19. En su opinión, ¿Por qué ninguna #sta…
Una pregunta muy necesaria
RT @StochasticVari1: Research by CEPI’s vaccine R&D team, published in Nature Reviews Drug Discovery, details the current state of the COVI…
RT @ADNDaniel: Hay más de 90 #vacunas candidatas en desarrollo para frenar la #pandemia de #covid19. En su opinión, ¿Por qué ninguna #sta…
RT @ADNDaniel: Hay más de 90 #vacunas candidatas en desarrollo para frenar la #pandemia de #covid19. En su opinión, ¿Por qué ninguna #sta…
Hay más de 90 #vacunas candidatas en desarrollo para frenar la #pandemia de #covid19. En su opinión, ¿Por qué ninguna #startup, empresa farmacéutica, universidad o centro de investigación de #Latinoamérica está participando en la carrera? https://t.co/8
The COVID-19 vaccine development landscape https://t.co/dmx87tC6Gj
RT @PhilProton: El 72% de candidatos para vacuna para el #COVIDー19 son desarrolladas en proyectos e inversión de la industria privada via @…
RT @PhilProton: El 72% de candidatos para vacuna para el #COVIDー19 son desarrolladas en proyectos e inversión de la industria privada via @…
@EfectoCocuyo Son 115 en total, los invito a leer nature https://t.co/pVg2FvOUu8
RT @PhilProton: El 72% de candidatos para vacuna para el #COVIDー19 son desarrolladas en proyectos e inversión de la industria privada via @…
RT @PhilProton: El 72% de candidatos para vacuna para el #COVIDー19 son desarrolladas en proyectos e inversión de la industria privada via @…
The global #COVID19vaccine R&D landscape includes 115 vaccine candidates, of which 78 are confirmed as active. @CEPIvaccines is working with global health authorities and #vaccine developers to continuously maintain an updated list. https://t.co/xiCqiB
RT @PhilProton: El 72% de candidatos para vacuna para el #COVIDー19 son desarrolladas en proyectos e inversión de la industria privada via @…
RT @PhilProton: El 72% de candidatos para vacuna para el #COVIDー19 son desarrolladas en proyectos e inversión de la industria privada via @…
RT @PhilProton: El 72% de candidatos para vacuna para el #COVIDー19 son desarrolladas en proyectos e inversión de la industria privada via @…
The COVID-19 vaccine development landscape https://t.co/lUcjg7L6Rs
RT @PhilProton: El 72% de candidatos para vacuna para el #COVIDー19 son desarrolladas en proyectos e inversión de la industria privada via @…
RT @PhilProton: El 72% de candidatos para vacuna para el #COVIDー19 son desarrolladas en proyectos e inversión de la industria privada via @…
El 72% de candidatos para vacuna para el #COVIDー19 son desarrolladas en proyectos e inversión de la industria privada via @Nature Nota completa: https://t.co/hNCMDam7d1 https://t.co/lm2CmeirDH
@EyeVey @LadyRedWave @CNN @realDonaldTrump @WhiteHouse There have been no “remarkable results so far.” Development of a vaccine can’t have begun before mid-January. https://t.co/vAZWeGO6rK
@faznet @jensspahn 5 years earliest. Here: The COVID-19 vaccine development landscape https://t.co/uVcCyrt3Vd
The COVID-19 vaccine development landscape https://t.co/OsQXbVAQNt
The COVID-19 vaccine development landscape https://t.co/fTpULFEcq6
India the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, and also supplies 50% of global demand for #vaccines Still not seen in the global picture for #COVID19 @kiranshaw @makeinindia https://t.co/FHnqx
RT @kamalkumarinder: The COVID-19 vaccine development landscape https://t.co/v8nrLm2Lf8
The COVID-19 vaccine development landscape https://t.co/v8nrLm2Lf8
RT @oatila: Pra quem perguntou sobre vacinas, a Nature soltou uma compilação ótima sobre iniciativas em andamento: https://t.co/8jYrc1fMkq…
@fdmiglioroma @nzingaretti @RegioneLazio Tieni, informati tu: 1) Glaxo https://t.co/9RcLeDbXXF 2)https://t.co/CJp6cI7UJN 3)https://t.co/Xa3E9UMu6N 4)https://t.co/TD3LiqX2lR 5)https://t.co/SO5cCUVlRn 6)https://t.co/1jnUQ4xAK7
RT @osakakyoto_0825: there is an indication that #vaccines could be available under emergency use or similar protocols by early 2021 先行する研究…
@westinghouse565 4/9のnatureの後中国のAd5-nCOVが第二相試験に進み英国オックスフォード大学とドイツ・米ファイザーのチームが臨床試験入りました。第一相と第二相を同時にする臨床試験もありますが私が見た限り記事の5+2チームは臨床試験に入ってます。阪大とアンジェスは3月末動物実験です https://t.co/z05dMr78s2
there is an indication that #vaccines could be available under emergency use or similar protocols by early 2021 先行する研究の緊急承認で2021年初頭 #WHO は2月に18ヶ月と言ってますので今年中の #ワクチン は厳しいです。普通は4~5年かかる話です #Covid_19 https://t.co/z05dMr78s2
@Trottski46 @NadineDorries @JamesDelingpole I don't think a 100 billion dollar man still thinks of money. And let science do her work. A lot of vaccines are undergoing development, and the global vaccine effort in response to the COVID-19 pandemic is unpre
@moneyhabist @PicuPiee @fakhrul2204 @asumsico Semua ada risk and benefit nya. "Given the imperative for speed, there is an indication that vaccines could be available under emergency use or similar protocols by early 2021." Sumber: https://t.co/9f5rqfOQB
RT @ymori117: Nature Reviews Drug Discovery: The COVID-19 vaccine development landscape https://t.co/TnPEqDpX76
Nature Reviews Drug Discovery: The COVID-19 vaccine development landscape https://t.co/TnPEqDpX76